FDA Staff Raises Efficacy Concerns Over Intercept’s Liver Disease Drug
The Food and Drug Administration (FDA Staff) has raised significant concerns about the effectiveness of a drug developed by Intercept Pharmaceuticals for treating liver disease. The drug, designed to combat nonalcoholic steatohepatitis (NASH), is now under scrutiny due to questions surrounding its efficacy and potential risks. This development could be a major roadblock for Intercept’s […]